Acumen Pharmaceuticals, Inc. (ABOS)
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Acumen Pharmaceuticals, Inc.
- sabirnetug (ACU193)READOUTCash runway at this date: 8mo
- sabirnetug (ACU193)READOUTCash runway at this date: 7mo
- Cash runway at this date: < 1 mo
Trials need funding. See this company's dilution risk and cash position.
- Phase 2Active, not recruiting
A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)
sabirnetug, Placebo
Alzheimer Disease
NCT06335173Enrollment542StartFeb 2024Primary CompletionOct 2026est.READOUTCompletionOct 2026est. - Phase 1Completed
A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD
ACU193, Placebo
Alzheimer Disease
NCT04931459Enrollment65StartJun 2021Primary CompletionJun 2023CompletionJun 2023 - Phase 1Completed
A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants
sabirnetug (ACU193)
Alzheimer Disease
NCT06511570Enrollment28StartJun 2024Primary CompletionSep 2024CompletionSep 2024
| Drug / Therapy | Link | ||
|---|---|---|---|
| Phase 2 | Active, not recruiting | sabirnetug, Placebo | NCT06335173 |
| Phase 1 | Completed | ACU193, Placebo | NCT04931459 |
| Phase 1 | Completed | sabirnetug (ACU193) | NCT06511570 |